Leuven, 23 December, 2016 – ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company developing novel medicines for back of the eye disease, with a focus on diabetic eye disease, today announced that the protocol of the Phase II CIRCLE Trial Evaluating Multiple Doses of THR-409 to induce a Total Posterior Vitreous Detachment in Patients with Non-Proliferative Diabetic Retinopathy (NPDR) has been amended.
The changes will allow inclusion of patients with less severe non-proliferative diabetic retinopathy (ETDRS level 43A - 47A). This will result in a broader patient pool for the study to recruit from.
The amended study, which focuses on assessing the ability of multiple doses of THR-409 to induce a total PVD in patients with NPDR, is now expected to enroll approximately 115 patients.
